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Abstract
Introduction. Obesity, hyperglycaemia, hyperlipidemia and hypertension are the hallmarks of metabolic syndrome. The 
epidemic of obesity has been accompanied by an analogous rise in the number of patients with metabolic syndrome. 
Thus, obesity and related metabolic disturbances are the main objective of public health throughout the world. Previously, 
we have shown that yohimbine, a non-selective α2-adrenergic receptor antagonist, reduces body weight and improves 
disrupted lipid and carbohydrates profiles in rats with diet-induced obesity.  
Material and method. In the presented study we have determined the effect of yohimbine on the body weight and 
carbohydrate and lipids levels in genetically obese leptin-deficient ob/ob mice and in lean C57BL6 mice.  
Results. Yohimbine had a favourable effect on elevated levels of triglycerides, cholesterol and glucose. However, it did not 
have any influence on body weight.  
Conclusions. The obtained data show that the weight reducing activity of yohimbine is primarily mediated via the interaction 
with α2-adrenergic receptor, and the subsequent enhanced release of noradrenaline which stimulates the β3-adrenergic 
receptor presented on adipocytes. The favourable influence of yohimbie on impaired lipid-carbohydrate homeostasis is 
achieved via the blockade of α1-adrenergic receptor. We believe that non-selective α-adrenoceptor antagonists might offer 
therapeutic benefits in the treatment of obesity and metabolic disturbances.
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INTRODUCTION
According to the World Health Organization (WHO), 
approximately one billion people worldwide are overweight, 
and among them more than 300 million are clinically 
obese [1]. Not surprisingly, the WHO has defined obesity 
as an epidemic of the 21st century. Obesity along with 
dyslipidaemia, hyperglycaemia and hypertension, is one of 
the main clusters of the metabolic syndrome. In recent years, 
the increasing prevalence of obesity has been accompanied by 
an analogous rise in the number of patients with metabolic 
syndrome [2]. Both conditions constitute a serious therapeutic 
challenge and place a heavy burden on the health care system. 
Moreover, long-lasting, untreated metabolic disorders have 
been associated with increased mortality [3]. This shows 
the importance of an urgent development for effective and 
safe therapies.
Leptin is a protein secreted by the adipose tissue which 
mediate an anorectic effect and leads to increased energy 
expenditure. It inhibits the biosynthesis of triacylglycerol 
in the liver, adipose tissue and skeletal muscle, resulting in 
a decreased amount of lipids in the cells. Moreover, leptin 
increases tissue sensitivity to insulin and thus improves 
glucose tolerance [4]. The ob/ob mice carry mutations that 
prevent the synthesis of leptin, and thus suffer from leptin 
deficiency and, as a result, are obese. Additionally, ob/ob 
mice possess several characteristics that mimic metabolic 
syndrome in humans such as: hyperglycaemia, elevated 
plasma cholesterol levels or hypertriglyceridaemia [5]. For 
this reason, ob/ob mice have been frequently used as an 
animal model of obesity and obesity-related metabolic 
disturbances [6].
Much literature data has suggested that drugs such as 
sibutramine, bromocriptine or bupropion, apart from having 
appetite suppressing properties, are effective in reducing 
body weight due to their influence on α2-adrenoreceptors 
[7, 8, 9]. The α-adrenoreceptors are widely distributed in 
the body and are involved in the control of the function 
of adipocytes and pancreatic islet β-cells, as well as blood 
pressure [10]. The interaction with α2-adrenoceptors can lead 
to areduction of body weight indirectly via the induction 
of lipolysis and thermogenesis, while the blockade of α1-
adrenoceptors can improve disrupted lipid and carbohydrate 
profiles [11]. Several components of the metabolic syndrome, 
such as: obesity, imbalanced lipid-carbohydrate homeostasis 
or hypertension, are associated with over-activation of the 
sympathetic nervous system [12]. For this reason, molecules 
which block α-adrenoceptors and can favourably modulate 
metabolic changes have attracted the interest of researchers.
Yohimbine is an indole based alkaloid isolated from 
the African tree Pausinystalia Yohimbe. It displays a wide 
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range of pharmacological activities, such as: hypotensive, 
antipsychotic or reducing body weight [13]. Additionally, 
yohimbine has been studied as a potential treatment of 
xerostomia and erectile dysfunction. Yohimbine is a non-
selective, potent antagonist of α2-adrenoreceptors. It also 
weakly interacts with the α1-adrenoreceptor type [11].
OBJECTIVES
Previously, we have found that yohimbine exerts an anorectic 
effect and consequently caused body weight reduction in 
an animal model of obesity induced by a high-fat diet. 
Additionally, yohimbine reduced the high glucose and 
triglyceride levels in the blood, which is believed to be 
mediated via the interaction with adrenergic receptors. As 
a continuation to our earlier experiments, in the presented 
study we attempted to assess the effect of a chronic 
administration of yohimbine on body weight in genetically 
obese leptin-deficient ob/ob mice, as well as to determine 
yohimbine’s influence on lipid and carbohydrate profiles. 
The effects of yohimbine in ob/ob animals were determined 
in parallel on C57BL6 mice.
MATERIALS AND METHOD
Determination of the effect of yohimbine on body weight 
in the ob/ob mice and C57BL6 mice. Six-week-old male 
C57BL6 mice were divided into 3 groups of 6 animals: a 
control group receiving intraperitoneal water (0.2 ml) and 
a group receiving intraperitoneal doses of yohimbine (2 or 
5 mg/kg) once per day in the morning between 09:00 – 10:00 
0er a 30-day period. C57BL6 mice received a standard feed 
(Labofeed, Morawski Feed record label, Poland) with water 
available ad libitum.
Six-week-old male ob/ob mice (Jackson Laboratory, USA) 
were divided into 2 groups of 6 animals: a control group 
receiving intraperitoneal water (0.2 ml) and a group receiving 
intraperitoneal doses of yohimbine (5 mg/kg) once per day 
in the morning between 09:00 -10:00 over a 30-day period. 
ob/ob Mice received feed as recommended by their breeder: 
JL Mouse Breeder Auto/no Hysil Labdiet (PMI NUTRITION 
INTL., LLC., England) with water available ad libitum. 
Intakes of food and water, and body weight were measured 
daily immediately prior to administration of drugs.
ll mice survived until the end of the experiment.
Biochemical analysis. On the 30th day of treatment, food 
was discontinued and on the 31st day plasma was collected 
from the animals from the carotid artery, 20 minutes after 
the intraperitoneal administration of heparin 500 j/animal 
and thiopental (70 mg/kg b.w.). Each sample was then frozen 
in liquid nitrogen before storage at −80 °C. Lipid profiles and 
glucose levels were determined. Standardized tests purchased 
from the Biomaxima Company S.A. (Poland) were used.
Statistical analysis. All statistical calculations were carried 
out with GraphPad Prism 6. Results were described as 
arithmetic means with standard errors of this mean (SEM). 
The statistical significance was calculated using a one-way 
analysis of variance (ANOVA) post-hoc Dunnett’s Multiple 
Comparison Test or two-way ANOVA post-hoc Bonferroni 
or Student’s t-test. Differences were considered statistically 
significant at p ≤ 0.05: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
RESULTS
Effects of yohimbine on body weight, level of food and water 
intake in C57BL6 mice treated for 30 days with yohimbine. 
The C57BL6 mice treated for 30 days with yohimbine at 5 mg/
kg b.w. had a statistically significantly lower body weight on 
day 30 compared to the control mice group. They gained 
significantly less weight than control group mice (two-way 
ANOVA). There were no significant differences in weight on 
the first and last day of treatment (one-way ANOVA). The 
control mice significantly increased body weight during the 
experiment (one-way ANOVA). Changes in body weight over 
the 30 days of the treatment are shown in Figure 1A.
The C57BL6 mice receiving intraperitoneal yohimbine did 
not consume less food and water compared to the control 
mice. Therefore, it can be concluded that weight loss was not 
the result of any anorexic impact. The amount of food and 
water consumed is presented in Figure 2.
Figure 1. Weight change and food and water intakes during the treatment of ob/
ob mice or C57BL6 mice with yohimbin.e
A: Weight change in C57BL6 mice treated for 30 days with the test compound: 
yohimbine at a dose of 2 mg/kg b.w., i.p.; yohimbine at a dose of 5 mg/kg b.w., i.p. 
or vehicle – water; Means ± SEM, n = 6; Significant to control group (vehicle C57BL6): 
*p < 0.05 (two-way ANOVA); B: Weight change in ob/ob mice treated for 30 days 
with yohimbine at a dose of 5 mg/kg b.w., i.p. or vehicle – water; Means ± SEM, n = 6
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Effects of yohimbine on body weight, level of food and 
water intakes and lipid and carbohydrate profiles in ob/
ob mice treated for 30 days with yohimbine. Yohimbine 
used at a dose of 5 mg/kg b.w. for 30 days had no statistically 
significant effect on the body weight of ob/ob mice. There 
were no statistically significant differences between the 
control and treated groups (two-way ANOVA). Both groups 
had significantly increased their weight (one-way ANOVA, 
p < 0.001 ***). Changes in body weight over the thirty 
days of treatment are shown in Figure 1B. The amount of 
ingested food and water is presented in Figure 2. Yohimbine 
administered for 30 days in ob/ob mice significantly reduced 
glucose levels and favorably affected the lipid profile (Student’s 
t-test). Results are shown in Figure 3.
DISCUSSION
Obesity is a key component of metabolic syndrome and an 
established risk factor for cardiovascular diseases. Obesity-
related cardiac risk factors, such as hyperinsulinaemia, 
hyperlipidaemia, hypertension, generalized inflammation 
and clotting abnormalities, are the targets for the treatment 
of obese patients who have not yet developed metabolic 
syndrome.. When untreated, these conditions can, in turn, 
lead to life-threatening heart disease [14].
The presented study was conducted to determine the effect 
of yohimbine on body weight and food intake in obese leptin-
deficient ob/ob mice and in their lean littermates: C57BL6 
mice. The study began from the determination of an effective 
dosage of yohimbine, during which a significant reduction of 
body weight in the C57BL6 mice could be observed For this 
purpose, 2mg/kg and 5mg/kg of yohimbine was administrated 
for 30 days to C57BL6 animals. It was observedthat 5mg/kg 
of yohimbine caused a significant reduction in body weight 
in C57BL6 mice. However, the amount of consumed food 
and water was not lower in comparison to the control group. 
Thus, It can conclude that the weight reduction activity was 
not a result of anorectic effect.
Chronic administration of 5mg/kg of yohimbine was next 
administered to obese leptin-deficient ob/ob mice to see if the 
Figure 2. Food and water intakes during the treatment of ob/ob mice or C57BL6 
mice with yohimbine.
Food and water intakes for 6 mice over 30 day treatment with test compound – 
yohimbine at a dose of 5 mg/kg b.w., i.p. in C57BL6 or ob/ob mice
Figure 3. Effects of yohimbine on biochemical parameters after administration 
of yohimbine to ob/ob mice.
Level of: A: Glucose, B: TG, C: Cholesterol, D: HDL, E: LDL. Means ± SEM, n= 6; 
Significant to control ob/ob group – vehicle ob/ob *p < 0.05 (Student’s t-test).
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yohimbine influenced any body weight changes. According 
to previous literature reports, higher dosages of yohimbine 
are not recommended as yohimbine might undesirably affect 
blood pressure and heart rate, due to interaction with the 
central and peripheral adrenoceptors [11]. Nevertheless, 
yohimbine administrated for 30 days at dosage of 5mg/kg, 
did not have a statistically significant effect on body weight 
or food and water intake in mice with genetically-induced 
obesity (ob/ob mice).
Ob/ob mice suffered from elevated noradrenaline levels in 
the ventromedial hypothalamic nuclei, a region in the brain 
which controls the peripheral lipid and glucose metabolism 
[15]. Additionally, the ventromedial hypothalamic nuclei are 
the main site of leptin activity. In the absence of leptin, as 
seen in ob/ob mice, some adrenergic receptor changes were 
observed. For instance, it has been stated that a decreased 
density of α2-adrenoreceptors in ob/ob mice leads to an 
increased release of noradrenaline, that potentiate the obese-
hyperglycemic state. Noradrenaline triggers hyperglycaemia 
and impaired lipid profiles in these animals through the 
stimulation of α1-adrenoceptors [15]. Additionally, much 
literature data showed that β3-adrenoceptor mRNA 
levels were considerably lower in white and brown adipose 
tissue of ob/ob mice, compared to lean mice [16]. β3-
adrenoceptors mediate lipolysis in white adipose tissue 
[17], while in brown adipose tissue β3-adrenoceptors trigger 
thermogenesis. Both effects contribute to the reduction of 
body weight [18].
The primary mechanism of the action of yohimbine is 
related with the blockade of presynaptic α2-adrenoreceptors 
which enhances the release of noradrenaline into the synaptic 
cleft. Noradrenaline, in turn, stimulates the β3-adrenoceptor, 
which undoubtedly results in the body weight reduction. 
This effect has been confirmed in the animal model of 
obesity induced by a high-fat diet [11]. Similarly, it can be 
assumed that the weight-reducing activity of yohimbine in 
the lean littermates C57BL6 mice is the result of interaction 
with α2-adrenoreceptors. However, the lack of any effect in 
reducing body weight after administration of yohimbine 
in genetically altered animals, might be related with the 
inability to interact with both α2- and β3-adrenoceptors, as 
their function are impaired in ob/ob mice. Thus, the obtained 
results in the current study concur with the authors’ previous 
findings that the effect of yohimbine in reducing body weight 
is mainly mediated via the blockade of α2-adrenoceptors, 
and consequently with the indirect stimulation of β3-
adrenoceptors by the released noradrenaline.
The presented study additionally determined the effect 
of yohimbine on the lipid and glucose profile. In contrast 
to the lack of weight reducing effects, a significant decrease 
was observed in the glucose level and improved lipid 
profiles in ob/ob mice, by means of a significant reduction 
of triglyceride, total cholesterol and low-density lipoprotein 
(LDL) levels. Similar results were observed in the authors’ 
previous studies which showed that yohimbine favourably 
moderates lipid and glucose profiles in obese rats, induced 
by a high-fat feed [11]. The influence on lipid profile is most 
likely related with the blocking effect on α1-adrenoceptor 
[19], as yohimbine interacts additionally with this type of 
adrenergic receptors. The α1-adrenoceptor blockade causes 
an enhancement of noradrenaline levels, which increases 
glucose entrance into adipocytes and consequently decreases 
the amount of glucose in the blood.
The current results show that yohimbine can favourably 
influence the imbalanced lipid-carbohydrate homeostasis in 
the presence of leptin deficiency and impaired function of α2- 
and β3-adrenoceptors. Many reports have shown an increasing 
number of patients suffering from leptin resistance constitute 
a serious therapeutic challenge. Therefore, the present results 
highlight the great potential of α1-adrenoceptor antagonists 
in the future treatment of disrupted lipid and carbohydrate 
profiles, particularly in patients with metabolic disorders 
and leptin resistance. Furthermore, yohimbine is frequently 
used in the treatment of erectile dysfunction in men. Some of 
these patients may suffer from disrupted lipid-carbohydrate 
homeostasis. Patients who have already implemented the 
treatment with yohimbine may additionally benefit from its 
favourable effects on the disrupted lipid and glucose profiles.
The auithors believe that α-adrenoceptor are an interesting 
therapeutic target and should be considered as a potential 
treatment for metabolic disturbances. Several components 
of the metabolic syndrome are related to an enhanced 
stimulation of the sympathetic nervous system [12]. Moreover, 
many undesirable reactions are mediated via the activation of 
α-adrenoceptors, and in particular enhanced the release of 
free fatty acids and glucose. Thus, targeting the over-activated 
sympathetic nervous system with adrenoceptor antagonists, 
appears to be a judicious and suitable therapeutic approach 
for the treatment of metabolic disturbances [20].
The authors recognized the following limitation of 
the current study: that although insulin levels were not 
determined during the experiments, such analysis might 
be of interest as α2-adrenoceptor antagonists can positively 
modulate the pancreatic function and control the secretion 
of insulin secretion. This issue will be considered in the 
authors’ future studies.
CONCLUSIONS
The study shows that α2-adrenoceptor antagonist yohimbine, 
reduced body weight in the C57BL6 mice, but not in obese 
leptin-deficient ob/ob mice. The α2-adrenoceptor antagonists 
unblocked the release of noradrenaline, which may increase 
the stimulation of β3-adrenoceptors and cause body weight 
reduction. In the absence of leptin, and the impaired function 
of α2 and β3-adrenoceptors, as seen in ob/ob mice, yohimbine 
is ineffective to provide weight reducing activity. However, 
yohimbine improved lipid and carbohydrate profiles in these 
animals, which is most likely related with the blockade of the 
α1-adrenoceptor, since yohimbine interacts additionally with 
α1-adrenoceptors in high dose. The authors believe that non-
selective α-adrenoceptor antagonists might offer therapeutic 
benefits in the treatment of disrupted lipid-carbohydrate 
homeostasis.
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